Tenaya Therapeutics opened higher at $0.37, compared with its previous close of $0.37. In the last trading session, the stock traded between $0.35 and $0.38. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Tenaya Therapeutics is now worth
$ 1.17
Resulting in a loss of
$ 98.83 (98.83%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.03 (-7.06%)
Day High
$0.38
Day Low
$0.35
Day Open
$0.37
Prev Close
$0.37
Volume
21,79,703
1W Return
-7.01%
1M Return
-39.58%
3M Return
-54.12%
6M Return
-65.43%
1Y Return
-75.70%
Market Cap ($ Mn)
79
PE Ratio
-
PB Ratio
2.23
PEG Ratio
-
ROE
-87.41%
ROCE
-82.33%
EPS (TTM)
$-0.08
1 Week
-7.01%
1 Month
-39.58%
3 Months
-54.12%
6 Months
-65.43%
9 Months
-49.24%
FDA grants RMAT designation to Tenaya Therapeutics TN-401 gene therapy
FDA grants RMAT designation to Tenaya Therapeutics gene therapy candidate TN-401. Therapy targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Decision supported by positive interim data from RIDGE-1 Phase 1b/2 trial. Trial results demonstrated reduced arrhythmia burden in treated patients. Company anticipates further regulatory updates in fourth quarter of 2026.
1mo agoTenaya Therapeutics to host investor meetings at Wainwright and Morgan Stanley conferences
Tenaya Therapeutics (NASDAQ: TNYA) will host investor meetings at the H.C. Wainwright and Morgan Stanley conferences on September 14 and 15, 2026. A fireside chat from the Wainwright event will be available on demand starting September 11, 2026, at 7:00 am ET. The company’s pipeline includes gene therapies TN-201 and TN-401 for cardiomyopathy, plus small molecule TN-301 for HFpEF and DMD.
2mo agoTenaya Therapeutics Q2 Results: Sales miss $10M estimate
Tenaya Therapeutics reported Q2 EPS of $(0.20), missing the $(0.05) estimate by 300%. Sales of $1.110M missed the $10.000M consensus by 88.90%. Losses widened from $(0.14) per share in the prior year period.
3mo agoTenaya Therapeutics grants inducement options to new CFO
Tenaya Therapeutics Inc. granted stock options for 1,650,000 shares to new CFO Eric Hyllengren and 187,200 shares to two new non-executive employees. The options are priced at $0.8365 per share and vest over four years. These inducement grants were made under the 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
4mo agoTenaya Therapeutics appoints Eric Hyllengren as CFO
Tenaya Therapeutics, Inc. appointed Eric Hyllengren as Chief Financial Officer effective July 13, 2026, to oversee financial strategy and capital allocation. Hyllengren brings over two decades of experience from roles at Zura Bio, Atara Biotherapeutics, and Amgen. The company also announced the retirement of Hiro Higa, Senior Vice President, Finance, in the third quarter of 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Tenaya Therapeutics is now worth
$ 1.17
Resulting in a loss of
$ 98.83 (98.83%)
Note: Past profits do not guarantee future returns.
